{"id":"W4295816936","doi":"10.1016/j.annonc.2022.07.179","title":"144P Neoadjuvant giredestrant (GDC-9545) + palbociclib (P) vs anastrozole (A) + P in postmenopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Biomarker subgroup analysis of the randomised, phase II coopERA BC study","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Anastrozole; Palbociclib; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Stage (stratigraphy); Gynecology; Cancer; Urology; Gastroenterology; Metastatic breast cancer; Tamoxifen; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008443803,0.0004921917,0.00199681,0.0006042434,0.000282349,0.00001127026,0.000452392,0.0001244855,0.001448643],"category_scores_gemma":[0.00004631377,0.0003504294,0.0002421256,0.003059513,0.0006480937,0.0001763018,0.0002409906,0.0004995984,0.000001828073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006072159,"about_ca_system_score_gemma":0.0008126367,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008705151,"about_ca_topic_score_gemma":0.002020513,"domain_scores_codex":[0.9955572,0.001125023,0.001056321,0.0007201636,0.0007267068,0.0008145503],"domain_scores_gemma":[0.9973056,0.0003300283,0.0008509262,0.0006616111,0.000605163,0.0002466389],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4060334,0.0189571,0.407265,0.00006663024,0.01902309,0.0004454749,0.01919923,0.004264326,0.05500014,0.0000236301,0.0002176622,0.06950428],"study_design_scores_gemma":[0.1002823,0.03883723,0.8428031,0.0001123787,0.0018806,0.0001094911,0.007874341,0.0002867972,0.006128867,0.00002104555,0.001222922,0.0004409286],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918143,0.0003335669,0.00001772601,0.003760935,0.0001041942,0.002304039,0.001475966,0.00003868191,0.000150617],"genre_scores_gemma":[0.9976474,0.0001014353,0.0001301342,0.0007917802,0.00004335237,0.0009068918,0.0001025863,0.00006870666,0.0002076894],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4355381,"threshold_uncertainty_score":0.9998948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0236514411366035,"score_gpt":0.3379894408180784,"score_spread":0.3143379996814749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}